

Mr. G van Emmenis The Acting Principal Officer **Bonitas Medical Fund** P O Box 1101 FLORIDA GLEN 1708

Ref: **BMU 1512** Eng: Mpho Sehloho t: 012 431 0533 f:

086 687 2275

m.sehloho@medicalschemes.com e: Date: 2 March 2017

Dear Mr. van Emmenis

2017 SUBSEQUENT RULE AMENDMENTS: MEDICAL SCHEMES ACT 131 OF 1998

Find herewith rule amendments duly approved and registered in terms of Section 31(3)(a). Also enclosed is an invoice for statutory fees in this regard.

Yours faithfully

Dr. S Kabane

Acting CE & Registrar

Council for Medical Schemes



Bonitas Medical Fund 37 Conrad Road, Florida North, 1709 P O Box 1101, Florida Glen, 1708 T 0860 00 2108

www.bonitas.co.za

We, the undersigned, hereby certify that in accordance with the provisions of the rules of the Fund, adopted the following rule amendments with the effect from 1 January 2017.

The appended documents are initialed for identification purposes.

Chairperson (activa)

Trustee

Acting Principal Executive Officer

Date

REGISTERED BY ME ON

REGISTRAR OF MEDICAL SCHEMES







BONITAS MEDICAL FUND AMENDMENTS 2017

ANNEXURE B BONCAP

D11.3	Amended to read: "40% co-payment applies for non formulary drugs used voluntarily."
D14.1	Amended to read: "40% co-pay for services rendered by non-ICON medical specialists, where such services are voluntarily obtained."

ANNEXURE B Standard, Standard Select and Primary

D11.3	All Options	Amended to read: "40% co-payment applies for non formulary
		drugs used voluntarily."

ANNEXURE B: BonComprehensive, BonClassic, BonComplete

D11.3	All Options	Amended to read: "40% co-payment applies for non formulary drugs used voluntarily."
D15	BonComplete	Removed: Limited to R5 550 per family; and "and/or above threshold benefit."
D15	BonComprehensive/ BonComplete	Changed "Acc: No" to "Acc: Yes"
D15.2	BonComplete	Changed R850 to R700
D15.3.1	BonComplete	Amended to read: 100% towards the cost of clear lenses, limited to R205 per lens per beneficiary.
D15.3.2	BonComplete	Amended to read: 100% towards the cost of clear lenses, limited to R475 per lens per beneficiary.
D15.3.3	BonComplete	Amended to read: • 100% towards the cost of clear lenses, limited to R825 per lens per beneficiary.
D15.3.4	BonComplete	Changed R1 850 to R 1 730


ANNEXURE B: BonSave, BonFit and BonEssential

D11.3	All Options	Amended to read: "40% co-payment applies for non formulary
		drugs used voluntarily."

ANNEXURE B: Hospital Standard and Hospital Plus

D13.2.1	Hospital Plus	Amended to read: "100% of the Bonitas Tariff for the general practitioner or medical specialist."

Version 1,0 (2016/12/12)



Page 1 of 2






ANNEXURE C 2016

3.4.9.7.12	Added: "based on evidence based medicine, taking into consideration cost-effectiveness and
	affordability;"

ANNEXURE D 2016



Version 1.0 (2016/12/12) Page 2 of 2



PARA GRAPH D11.1	BENEFIT (EXCEPT FOR PMBs) Routine /(acute) medicine	Subject to the DSP network and the BonCap medicine formulary. Included in (D5.1.3).
D11.1.1	Medicine on discharge from hospital (TTO)	Limited to and included in D7.1.2.
D11.2	Pharmacy Advised Therapy Schedules 0, 1 and 2 medicine advised and dispensed by a pharmacist	Limited to R85 per event and maximum R235 per beneficiary per annum.
D 	Chronic medicine (See B2)	Prescribed Minimum Benefits only at contracted provider and subject to the formulary. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP. REGISTERED BY ME ON REGISTERAR OF MUDICAL SCHLMFS

ANNEXURE B 2017

HOSPITAL STANDARD AND HOSPITAL PLUS OPTIONS

		-		
PARA GRAPH	D13.2.1	D13.3	D13.3.1	D13.3.2
BENEFIT (EXCEPT FOR PMBs)	Routine diagnostic upper and lower gastro-intestinal fibre-optic endoscopy (excluding rigid sigmoldoscopy and anoscopy) 24 hr oesophageal PH studies Breast fine needle biopsy Circumcision Cystoscopy Laser tonsillectomy Oesophageal motility studies Vasectomy Prostate needle biopsy (See B1)	Sleep studies (See B1)	Diagnostic Polysomnograms In and out of hospital	CPAP Titration
			No b	No b
HOSPITAL STANDARD	No limit. 130% of the Bonitas Tariff for network specialists. 100% of the Bonitas Tariff for the non-network specialist or general practitioner.		No benefit.	No benefit.
	• •		No	S S
HOSPITAL PLUS	No limit. 100% of the Bonitas Tariff for the general practitioner or medical specialist.		No benefit,	No benefit.
CONDITION/REMARKS SUBJECT TO PMB	On Hospital Plus, the medical practitioner will be reimbursed at 200% of the Bonitas Tariff if done in hospital and pre-authorised by the relevant healthcare programme. Includes related consultation, materials, pathology and radiology if done in the rooms on the same day.			



Limited to and included in D14.1 and the formulary and subject to the DSP.
40% co-pay for services rendered by non-ICON medical specialists, where such services are voluntarily obtained.
The ICON medical specialist network is the DSP for oncology services (excluding paediatric oncology and acute haematology), at the negotiated rate.
·

D11.4.1	D11.4	D11.3.1	D11.3	PARA GRAPH
Non Oncology Biological Drugs applicable to monoclonal antibodies interleukins	Specialised Drugs (See B4)	MDR and XDR-TB	Chronic medicine (See B4)	BENEFIT (EXCEPT FOR PMBs)
No benefit, unless PMB.		No limit, subject to managed care protocols.	 Limited to R8 650 per beneficiary. R17 350 per family. 40% co-payment applies for non-formulary drugs. Above limits, PMBs and DSP apply. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP. 	STANDARD
No benefit, unless PMB.		No limit, subject to managed care protocols.	• Subject to the DSP and limited to R8 650 per beneficiary and R17 350 per family. • 40% co-payment applies for the voluntary use of a non-DSP. • Only PMBs will be paid above limits and 40% co-payment applies for nonformulary drugs used voluntarily and for the voluntary use of a non-DSP. REGISTERED BY REGISTERED BY	STANDARD SELECT
No benefit, unless PMB.		No limit, subject to managed care protocols.	Prescribed Minimum Benefits only at the DSP. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP. ME ON NE O	PRIMARY
Subject to the relevant managed healthcare programme and to its prior authorisation		Subject to the relevant managed healthcare programme and its prior authorisation.	Subject to registration on the relevant managed healthcare programme and to its prior authorisation and applicable formularies. Restricted to a maximum of one month's supply unless pre-authorised. [Includes diabetic disposables such as syringes, needles, strips and lancets The above are excluded from D3 and D11 if on the Diabetic Management Programme. This benefit excludes: In hospital medicine (D7): Anti-retroviral drugs (D8); Oncology medicine (D14); Organ and haemopoietic stem cell (bone marrow) transplantation and immuno-suppressive medication (D16).	CONDITIONS/REMARKS SUBJECT TO PMB

D11.3.1	ນ	PARA GRAPH
MDR and XDR-TB	(See B4)	(EXCEPT FOR PMBs)
• •	• • • •	
No limit. Subject to managed care protocols.	R24 800 per family. R12 450 per beneficiary. As specified in Annexure D paragraph 6.4.3. 40% co-payment applies for non formulary drugs used voluntarily.	BONCOMPREHENSIVE
• •	∞ • • • •	
No limit. Subject to managed care protocols.	R21 100 per family. R10 200 per beneficiary. As specified in Annexure D paragraph 6.4.3. Above limits, PMBs and DSP apply. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP. REGISTERED BY ME ON REGISTERED BY ME ON	BONCLASSIC
• •	Q S S S S S S S S S S S S S S S S S S S	
No limit. Subject to managed care protocols.	Prescribed Minimum Benefits plus the 4 conditions for children, as specified in Annexure D paragraph 6.4.3, at the DSP. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP.	BONCOMPLETE
	Subject to registration on the relevant managed healthcare programme and to its prior authorisation and applicable formularies. Restricted to a maximum of one month's supply unless pre-authorised. Includes diabetic disposables such as syringes, needles, lancets for patients not registered on the Diabetic Management Programme. This benefit excludes: In hospital medicine (D7); Anti-retroviral drugs (D8); Oncology medicine (D14); Organ and haemopoietic stem cell (bone marrow) transplantation immunosuppressive medication (D16). Acc: No	CONDITION/REMARKS SUBJECT TO PMB

	D15.3.2	ာ တ ယ	D15.3	D15.2	D15.1	D15	PARA
	Birocal lenses	Single vision lenses	Lenses	Frames	Optometric refraction test, re-exam and/or composite exam	OPTOMETRY (In and Out of Network) (See B4)	BENEFIT (EXCEPT FOR PMBs)
	D15.	Limited to and included in D15.		Limited to and included in D15.	Limited to and included in D15.	 Limited to R2 880 per beneficiary. Subject to savings and/or threshold. 	BONCOMPREHENSIVE
•	• •	• • •		• •	• • •		\neg
in D15; or	100% towards the cost of clear lenses at network rates. Limited to R325 per lens per beneficiary out of network.	100% towards the cost of clear lenses at network rates. Limited to R150 per lens per beneficiary out of network. Limited to and included in D15; or		R740 per beneficiary in and out of network. Limited to and included in D15.	One per beneficiary at network rates. R350 out of network. Limited to and included in D15.	Limited to R5 300 per family. Biennial benefit. Benefit availability is subject to a 24 month cycle from last date of service.	BONCLASSIC
	•	•		• •	• • •	• • •	
	100% towards the cost of clear lenses, limited to R475 per lens per beneficiary. Limited to and included in D15; or	100% towards the cost of clear lenses, limited to R205 per lens per beneficiary. Limited to and included in D15; or		R700 per beneficiary in and out of network. Limited to and included in D15.	One per beneficiary at network rates. R350 out of network. Limited to and included in D15.	Subject to available savings. Biennial Benefit. Benefit availability is subject to a 24 month cycle from last date of service.	BONCOMPLETE
		Subject to contracted providers protocols.		Including repairs.		Subject to the preferred provider. Frames and/or lenses are mutually exclusive to contact lenses. Acc: Yes	CONDITION/REMARKS SUBJECT TO PMB



GRAPH	(EXCEPT FOR PMBs)	CONCOUNT NEITHORA	Concerning	DONCOMPLE
D15.3.3	Multifocal lenses	Limited to and included in D15.	 100% towards the cost of clear lenses at network rates. Limited to R700 per lens per beneficiary out of network. Limited to and included in D15. 	 100% towards the cost of clear lenses, limited to R825 per lens per beneficiary. Limited to and included in D15.
D15.3.4	Contact lenses	 Limited to and included in D15. Limited and included in D15 except for Keratoconus where it is limited to R2 000 included in D3.1.1. 	 Limited to R1 790 per beneficiary. Limited and included in D15. 	 Limited to R1 730 per beneficiary. Limited and included in D15.
D15.4	Low vision appliances	Limited to and included in D3.1.1.	Limited to and included in D3.1.1.	Limited to and included in D3.1.1.
D15.5	Ocular prostheses	Limited to and included in D20.2.	Limited to and included in D20.2.	Limited to and included in D20.2.
D15.6	Diagnostic procedures	Limited to and included in D15.	Limited to and included in D15.	Limited to and included in D15.
D15.7	Readers			
D15.7.1	From a registered optometrist, ophthalmologist or supplementary optical practitioner	Limited to and included in D15. REC	No benefit ISTERED BY ME ON	Limited to and included in D15.

REGISTRAR OF MEDICAL SCHEMES

D11.4	D11.3.1	D11.3	PARA GRAPH
Specialised Drugs (See B4)	MDR and XDR-TB	Schedules 0, 1 and 2 medicine advised and dispensed by a pharmacist Chronic medicine (See B4)	BENEFIT FOR PMBs)
	No limit, subject to managed care protocols.	Prescribed Minimum Benefits only at the DSP. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP.	BONSAVE
	No limit, subject to managed care protocols.	Prescribed Minimum Benefits only at the DSP. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP. REGISTERED BY ME REGISTERAR OF MEDICAL SO REGISTERAR OF MEDICAL SO	BONFIT
	No limit, subject to managed care protocols.	Prescribed Minimum Benefits only at the DSP. 40% co-payment applies for non-formulary drugs used voluntarily and for the voluntary use of a non-DSP. ME ON ME ON ALSC HEMES	BONESSENTIAL
prior authorisation.	Subject to the relevant managed healthcare programme and its	Subject to registration on the relevant managed healthcare programme and to its prior authorisation and applicable formularies. Restricted to a maximum of one month's supply unless pre-authorised. [Includes diabetic disposables such as syringes, needles, strips and lancets The above are excluded from D3 and D11 if on the Diabetic Management Programme. This benefit excludes: In hospital medicine (D7); Anti-retroviral drugs (D8); Oncology medicine (D14); Organ and haemopoietic stem cell (bone marrow) transplantation and immunosuppressive medication (D16).	CONDITIONS/REMARKS SUBJECT TO PMB

3.4.9.11	medicines not approved by the Medicine Control Council unless Section 21 approval is obtained and pre-authorised by the relevant managed healthcare programme;			
3.4.9.12	medicines not authorised by the relevant managed healthcare programme based on evidence based medicine, taking into consideration cost-effectiveness and affordability;			
3.4.9.13	patent medicines, household remedies and proprietary preparations and preparations not otherwise classified;			
3.4.9.14	slimming preparations for obesity;			
3.4.9.15	smoking cessation and anti-smoking preparations, unless authorised as part of the wellness extender benefit. Excluded on BonCap;			
3.4.9.16	tonics, evening primrose oil, fish liver oils, multi-vitamin preparations and/or trace elements and/or mineral combinations (except for registered products that include haemotonics and those for use by infants and pregnant mothers);			
3.4.9.17	biological drugs except on BonComprehensive, BonClassic and Hospital Plus and Beta-Interferon for the treatment of Multiple Sclerosis as per the PMB algorithm unless specifically provided for in Annexure B;			
3.4.9.18	all benefits for clinical trials and all treatment / admission costs relating to complications of trial drugs, unless pre-authorised by the relevant managed healthcare programme;			
3.4.9.19	diagnostic agents, unless authorised;			
3.4.9.20	growth hormones, unless pre-authorised;			
3.4.9.21	immunoglobulins and immune stimulants, oral and parenteral, unless pre-authorised;			
3.4.9.22	medicines used specifically to treat alcohol and drug addiction, unless PMB. REGISTERED BY ME ON			

3.4.10 Mental health

3.4.10.1 Sleep therapy;



BONCOMPREHENSIVE OPTION

Acne

Allergic Rhinitis

Alzheimer disease (early onset)

Ankylosing Spondylitis

Anorexia Nervosa

Attention Deficit Disorder - In children 5-18 years old

Behcet's Disease

Barrett's Oesophagus

Bulimia Nervosa

Cystic Fibrosis

Dermatitis

Dermatomyositis

Depression

Eczema

Gastro-Oesaphageal Reflux (GORD)

Generalized Anxiety Disorder

Gout

Huntington's Disease

Hyperthyroidism

Myaesthenia Gravis

Narcolepsy

Neuropathies

Obsessive Compulsive Disorder

Osteoporosis

Paget's Disease

Panic Disorder

Polyarteritis Nodosa

Post-Traumatic Stress Syndrome

Psoriatic Arthritis

Pulmonary Interstitial Fibrosis

Systemic Sclerosis

Tourette's Syndrome

Zollinger-Ellison Syndrome

STANDARD AND STANDARD SELECT OPTIONS

Acne

Allergic Rhinitis

Ankylosing Spondylitis

Attention Deficit Disorder - in children 5-18 years

Barrett's Oesophagus

Behcet's Disease

Dermatitis

Depression

Eczema

Gastro-Oesaphageal Reflux (GORD)

Gout

Narcolepsy


Obsessive Compulsive Disorder

Panic Disorder

Post-Traumatic Stress Syndrome

Tourette's Syndrome

Zollinger-Ellison Syndrome



Page 7 of 16